drugset / Trial / NCT00135941

Insulin Glargine Plus Insulin Glulisine Multiple Daily Injections (MDI) Versus Premix Insulin Treatment in Subjects With Diabetes Mellitus (Type 1 or Type 2)

NCT00135941

Phase 3 Completed 582 enrolled Sanofi
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to test for superiority in improvements from baseline in patient reported outcomes in subjects with type 1 or type 2 diabetes when treated with insulin glargine plus rapid acting insulin glulisine MDI versus treatment with premix insulin.

Timeline

Start
2005-08
Primary completion
Completion
2007-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Insulin glulisine Protein / enzyme biologic
Subject insulin glargine Protein / enzyme biologic

Indications